Hartaj Singh
Stock Analyst at Oppenheimer
(1.56)
# 3,012
Out of 4,814 analysts
102
Total ratings
40.62%
Success rate
-11.47%
Average return
Main Sectors:
Stocks Rated by Hartaj Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Maintains: Outperform | $115 → $132 | $104.53 | +26.28% | 14 | Mar 4, 2025 | |
| SPRB Spruce Biosciences | Downgrades: Perform | n/a | $0.12 | - | 6 | Dec 11, 2024 | |
| ATXS Astria Therapeutics | Maintains: Outperform | $26 → $28 | $4.03 | +594.79% | 6 | Nov 14, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,150 → $1,000 | $563.16 | +77.57% | 12 | Nov 6, 2024 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $284.73 | +110.73% | 7 | Oct 31, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $550 → $540 | $489.10 | +10.41% | 16 | Oct 30, 2024 | |
| MRNA Moderna | Downgrades: Perform | n/a | $24.73 | - | 8 | Sep 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $1.43 | +599.30% | 5 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $1.70 | +3,429.41% | 5 | May 30, 2024 | |
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $180 | $53.79 | +234.63% | 9 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $1.79 | +402.79% | 4 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $1.74 | +2,198.85% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $8.15 | +169.94% | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $16 | $3.41 | +369.21% | 3 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $650 | $1.30 | +49,900.00% | 1 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $24.61 | +21.90% | 1 | Jan 26, 2018 |
Gilead Sciences
Mar 4, 2025
Maintains: Outperform
Price Target: $115 → $132
Current: $104.53
Upside: +26.28%
Spruce Biosciences
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $0.12
Upside: -
Astria Therapeutics
Nov 14, 2024
Maintains: Outperform
Price Target: $26 → $28
Current: $4.03
Upside: +594.79%
Regeneron Pharmaceuticals
Nov 6, 2024
Maintains: Outperform
Price Target: $1,150 → $1,000
Current: $563.16
Upside: +77.57%
United Therapeutics
Oct 31, 2024
Maintains: Outperform
Price Target: $575 → $600
Current: $284.73
Upside: +110.73%
Vertex Pharmaceuticals
Oct 30, 2024
Maintains: Outperform
Price Target: $550 → $540
Current: $489.10
Upside: +10.41%
Moderna
Sep 13, 2024
Downgrades: Perform
Price Target: n/a
Current: $24.73
Upside: -
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $1.43
Upside: +599.30%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $1.70
Upside: +3,429.41%
Sarepta Therapeutics
May 14, 2024
Upgrades: Outperform
Price Target: $180
Current: $53.79
Upside: +234.63%
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $1.79
Upside: +402.79%
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $1.74
Upside: +2,198.85%
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $8.15
Upside: +169.94%
Sep 13, 2023
Maintains: Outperform
Price Target: $31 → $16
Current: $3.41
Upside: +369.21%
Nov 1, 2018
Initiates: Outperform
Price Target: $650
Current: $1.30
Upside: +49,900.00%
Jan 26, 2018
Maintains: Outperform
Price Target: $24 → $30
Current: $24.61
Upside: +21.90%